(Q50602023)

English

Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial.

scientific article published in August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. (English)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

phase III clinical trial

0 references

0 references

darbepoetin alfa

0 references

object named as

Inder S Anand

2

0 references

Christopher M O'Connor

5

object named as

Christopher O'Connor

1 reference

Europe PubMed Central

16 March 2018

10

object named as

Karl Swedberg

1 reference

Europe PubMed Central

16 March 2018

Michał Tendera

11

object named as

Michal Tendera

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Dirk J van Veldhuisen

12

object named as

Dirk J van Veldhuisen

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Aldo P. Maggioni

object named as

Aldo P Maggioni

4

0 references

1

object named as

John J V McMurray

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Scott M. Wasserman

13

object named as

Scott M Wasserman

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

6

object named as

Marc A Pfeffer

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Krishna R. Polu

7

object named as

Krishna R Polu

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

author name string

Rafael Diaz

3

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Scott D Solomon

8

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Yan Sun

9

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

James B Young

14

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

RED-HF Committees and Investigators

15

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

publication date

1 August 2009

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

European Journal of Heart Failure

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

11

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

8

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

795-801

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Anemia and heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Anemia and its relationship to clinical outcome in heart failure.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Heart failure and anemia: mechanisms and pathophysiology.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Anemia and mortality in heart failure patients a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Tumor progression associated with erythropoiesis-stimulating agents

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Fatigue and anaemia in patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Using measures of disease progression to determine therapeutic effect: a sirens' song

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFP098

21 January 2018

Identifiers

10.1093/EURJHF/HFP098

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/19633103

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50602023&oldid=1744703558"